OMGA Stock Analysis
OM
Uncovered
Omega Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 116 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in a systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. The company has deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains (IGDs). The OMEGA platform enables to systematically identify and validate thousands of DNA-sequence-based epigenomic zip codes within IGDs. Its pipeline consists of early-stage, preclinical programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.